Difference between revisions of "Idarubicin (Idamycin)"
m (→References) |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Acute lymphocytic leukemia]] | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| Line 16: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 9/27/1990: Initial FDA approval | * 9/27/1990: Initial FDA approval | ||
| + | * 12/4/2014 (most recent label available on Drugs @ FDA): "in combination with other approved antileukemic drugs is indicated for the treatment of [[Acute myeloid leukemia|acute myeloid leukemia (AML)]] in adults. This includes French-American- British (FAB) classifications M1 through M7." | ||
==Also known as== | ==Also known as== | ||
| Line 31: | Line 33: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
| + | [[Category:Acute lymphocytic leukemia medications]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:Drugs FDA approved in 1990]] | [[Category:Drugs FDA approved in 1990]] | ||
Revision as of 00:27, 11 December 2015
General information
Class/mechanism: Anthracycline analog of Daunorubicin (Cerubidine), binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.[1][2][3][4]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Idarubicin (Idamycin) patient drug information (Chemocare)[5]
- Idarubicin (Idamycin) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 9/27/1990: Initial FDA approval
- 12/4/2014 (most recent label available on Drugs @ FDA): "in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American- British (FAB) classifications M1 through M7."
Also known as
Idamycin, Idamycin PFS, Idaru, idarubicin comp, idarubicin hydrochloride, Ondarubin, Zanedos, Zavedose
References
- ↑ 1.0 1.1 Idarubicin (Idamycin) package insert
- ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) package insert
- ↑ Idarubicin (Idamycin) package insert (locally hosted backup)
- ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)
- ↑ Idarubicin (Idamycin) patient drug information (Chemocare)
- ↑ Idarubicin (Idamycin) patient drug information (UpToDate)